Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27697313 | 0.90 | FGFR1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3773304 | 0.90 | FGFR1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2651919 | 0.90 | FGFR1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2652350 | 0.90 | FGFR1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27697316 | 0.87 | FGFR1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL13933284 | 0.85 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1762205 | 0.83 | FGFR1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1761658 | 0.83 | FGFR1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2651820 | 0.82 | FGFR1 (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1761775 | 0.79 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851490-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| US-7851490-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| US-7851490-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1877052-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-07-22 | — | — | EP | disclosed |
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| CN-101141958-A | Benzimidazole derivatives and their use for modulating GABAAUse of receptor complexes | NEUROSEARCH AS (DK) | 2008-03-12 | — | — | CN | disclosed |
| EP-1877052-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006108800-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108800-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | GABRB2, GABRB1, GABRB3 | GABRA1 7/4885GABRG2 20/4885GABRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.